{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:54:56Z","timestamp":1792598096402,"version":"4.5.0"},"reference-count":21,"publisher":"MyJove Corporation","issue":"219","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/67747","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T19:01:22Z","timestamp":1748026882000},"source":"Crossref","is-referenced-by-count":0,"title":["Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis"],"prefix":"10.3791","author":[{"given":"Qian","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhui","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongyuan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dansha","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"issue":"3","key":"ref1","doi-asserted-by":"crossref","first-page":"e12127","DOI":"10.1002\/pul2.12127","type":"journal-article","article-title":"Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertension","volume":"12","author":"Sm","year":"2022","unstructured":"Sm, N. et al. Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertension. Pulm Circ. 12 (3), e12127 (2022).","journal-title":"Pulm Circ"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"1801914","DOI":"10.1183\/13993003.01914-2018","type":"journal-article","article-title":"Pulmonary hypertension in chronic lung disease and hypoxia","volume":"53","author":"Nathan","year":"2019","unstructured":"Nathan, S. D. et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Resp J. 53 (1), 1801914 (2019).","journal-title":"Eur Resp J"},{"issue":"4","key":"ref3","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.chest.2020.04.046","type":"journal-article","article-title":"The Trouble With Group 3 Pulmonary Hypertension in Interstitial Lung Disease","volume":"158","author":"King","year":"2020","unstructured":"King, C. S., Shlobin, O. A. The Trouble With Group 3 Pulmonary Hypertension in Interstitial Lung Disease. Chest. 158 (4), 1651-1664 (2020).","journal-title":"Chest"},{"issue":"5","key":"ref4","first-page":"343","type":"journal-article","article-title":"Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis","volume":"11","author":"Meyer","year":"2017","unstructured":"Meyer, K. C. Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis. Expert Rev Respir Med. 11 (5), 343-359 (2017).","journal-title":"Expert Rev Respir Med"},{"issue":"9","key":"ref5","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","type":"journal-article","article-title":"Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"205","author":"Raghu","year":"2022","unstructured":"Raghu, G. et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Critic Care Med. 205 (9), e18-e47 (2022).","journal-title":"Am J Respir Critic Care Med"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12931-020-01570-2","type":"journal-article","article-title":"Pulmonary hypertension secondary to pulmonary fibrosis: clinical data, histopathology and molecular insights","volume":"21","author":"Ruffenach","year":"2020","unstructured":"Ruffenach, G., Hong, J., Vaillancourt, M., Medzikovic, L., Eghbali, M. Pulmonary hypertension secondary to pulmonary fibrosis: clinical data, histopathology and molecular insights. Respir Res. 21 (1), 303 (2020).","journal-title":"Respir Res"},{"issue":"5","key":"ref7","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s10565-021-09676-z","type":"journal-article","article-title":"Animal models of drug-induced pulmonary fibrosis: an overview of molecular mechanisms and characteristics","volume":"38","author":"Li","year":"2022","unstructured":"Li, S., Shi, J., Tang, H. Animal models of drug-induced pulmonary fibrosis: an overview of molecular mechanisms and characteristics. Cell Biol Toxicol. 38 (5), 699-723 (2022).","journal-title":"Cell Biol Toxicol"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1096\/fj.14-260182","type":"journal-article","article-title":"Deletion of ADORA2B from myeloid cells dampens lung fibrosis and pulmonary hypertension","volume":"29","author":"Karmouty-Quintana","year":"2015","unstructured":"Karmouty-Quintana, H. et al. Deletion of ADORA2B from myeloid cells dampens lung fibrosis and pulmonary hypertension. FASEB J. 29 (1), 50-60 (2015).","journal-title":"FASEB J"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/bph.15285","type":"journal-article","article-title":"Dysregulation of BMP9\/BMPR2\/SMAD signalling pathway contributes to pulmonary fibrosis and pulmonary hypertension induced by bleomycin in rats","volume":"178","author":"Jiang","year":"2021","unstructured":"Jiang, Q. et al. Dysregulation of BMP9\/BMPR2\/SMAD signalling pathway contributes to pulmonary fibrosis and pulmonary hypertension induced by bleomycin in rats. Br J Pharmacol. 178 (1), 203-216 (2021).","journal-title":"Br J Pharmacol"},{"issue":"6","key":"ref10","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/MAJ.0b013e31821aa000","type":"journal-article","article-title":"Progress toward improving animal models for idiopathic pulmonary fibrosis","volume":"341","author":"Degryse","year":"2011","unstructured":"Degryse, A. L., Lawson, W. E. Progress toward improving animal models for idiopathic pulmonary fibrosis. Am J Med Sci. 341 (6), 444-449 (2011).","journal-title":"Am J Med Sci"},{"issue":"19","key":"ref11","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1111\/bph.13947","type":"journal-article","article-title":"Inhibition of hyaluronan synthesis attenuates pulmonary hypertension associated with lung fibrosis","volume":"174","author":"Collum","year":"2017","unstructured":"Collum, S. D. et al. Inhibition of hyaluronan synthesis attenuates pulmonary hypertension associated with lung fibrosis. Br J Pharmacol. 174 (19), 3284-3301 (2017).","journal-title":"Br J Pharmacol"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s12931-023-02595-z","type":"journal-article","article-title":"Animal models of acute exacerbation of pulmonary fibrosis","volume":"24","author":"Ye","year":"2023","unstructured":"Ye, X. et al. Animal models of acute exacerbation of pulmonary fibrosis. Respir Res. 24 (1), 296 (2023).","journal-title":"Respir Res"},{"issue":"172","key":"ref13","first-page":"e62697","type":"journal-article","article-title":"Three-Dimensional Collagen Matrix Scaffold Implantation as a Liver Regeneration Strategy","author":"Le\u00f3n-Mancilla","year":"2021","unstructured":"Le\u00f3n-Mancilla, B. et al. Three-Dimensional Collagen Matrix Scaffold Implantation as a Liver Regeneration Strategy. J Vis Exp. (172),e 62697 (2021).","journal-title":"J Vis Exp"},{"issue":"146","key":"ref14","first-page":"e59130","type":"journal-article","article-title":"Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution","author":"Oldham","year":"2019","unstructured":"Oldham, S., Rivera, C., Boland, M. L., Trevaskis, J.L. Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution. J Vis Exp. (146), e59130 (2019).","journal-title":"J Vis Exp"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s12931-024-02916-w","type":"journal-article","article-title":"Nephrectomy and high-salt diet inducing pulmonary hypertension and kidney damage by increasing Ang II concentration in rats","volume":"25","author":"Jiang","year":"2024","unstructured":"Jiang, Q. et al. Nephrectomy and high-salt diet inducing pulmonary hypertension and kidney damage by increasing Ang II concentration in rats. Respir Res. 25 (1), 288 (2024).","journal-title":"Respir Res"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"L152","DOI":"10.1152\/ajplung.00313.2007","type":"journal-article","article-title":"Murine models of pulmonary fibrosis","volume":"294","author":"Moore","year":"2008","unstructured":"Moore, B. B., Hogaboam, C. M. Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 294 (2), L152-160 (2008).","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"5","key":"ref17","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1165\/rcmb.2017-0096ST","type":"journal-article","article-title":"An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis","volume":"56","author":"Jenkins","year":"2017","unstructured":"Jenkins, R. G. et al. An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis. Am J Respir Cell Mol Biol. 56 (5), 667-679 (2017).","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"7","key":"ref18","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1097\/CCM.0b013e31817d1a92","type":"journal-article","article-title":"The effects of estrogen on pulmonary artery vasoreactivity and hypoxic pulmonary vasoconstriction: Potential new clinical implications for an old hormone","volume":"36","author":"Lahm","year":"2008","unstructured":"Lahm, T. et al. The effects of estrogen on pulmonary artery vasoreactivity and hypoxic pulmonary vasoconstriction: Potential new clinical implications for an old hormone. Crit Care Med. 36 (7), 2174-2183 (2008).","journal-title":"Crit Care Med"},{"issue":"12","key":"ref19","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1111\/bph.15000","type":"journal-article","article-title":"Tetramethylpyrazine: A promising drug for the treatment of pulmonary hypertension","volume":"177","author":"Chen","year":"2020","unstructured":"Chen, Y. et al. Tetramethylpyrazine: A promising drug for the treatment of pulmonary hypertension. Br J Pharmacol. 177 (12), 2743-2764 (2020).","journal-title":"Br J Pharmacol"},{"issue":"5","key":"ref20","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/bph.15696","type":"journal-article","article-title":"Established pulmonary hypertension in rats was reversed by a combination of a HIF-2\u03b1 antagonist and a p53 agonist","volume":"179","author":"Zheng","year":"2022","unstructured":"Zheng, Q. et al. Established pulmonary hypertension in rats was reversed by a combination of a HIF-2\u03b1 antagonist and a p53 agonist. Br J Pharmacol. 179 (5), 1065-1081 (2022).","journal-title":"Br J Pharmacol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.thromres.2022.08.006","type":"journal-article","article-title":"Upregulation of mechanosensitive channel Piezo1 involved in high shear stress-induced pulmonary hypertension","volume":"218","author":"Chen","year":"2022","unstructured":"Chen, J. et al. Upregulation of mechanosensitive channel Piezo1 involved in high shear stress-induced pulmonary hypertension. Thrombo Res. 218, 52-63 (2022).","journal-title":"Thrombo Res"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/app.jove.com\/t\/67747\/establishment-validation-rat-model-pulmonary-arterial-hypertension","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:23:08Z","timestamp":1792596188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jove.com\/t\/67747\/establishment-validation-rat-model-pulmonary-arterial-hypertension"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":21,"journal-issue":{"issue":"219","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3791\/67747","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]}}}